Table 4.

Predictors of LTFU among HIV-positive adults using ART at hospitals of Kembata zone and Tembaro special district in Central Ethiopia, 2022 (n = 432).

Variables	Categories	LTFU		CHR (95% CI)	AHR (95% CI)
		Yes	No
Other HIV-Positive Family Members	Yes	58	142	Ref	Ref
	No	114	118	1.76 (1.28, 2.42)	1.39 (0.86, 2.22)
Disclose HIV Status	Yes	72	89	Ref	Ref
	No	100	171	2.24 (1.65, 2.03)	1.96 (1.14, 3.36)*
Living Condition	With parents	37	122	Ref	Ref
	Alone	135	138	1.87 (1.38, 2.53)	0.85 (0.41, 1.72)
Caregiver	Self	72	171	1.93 (1.43, 2.61)	0.81 (0.38, 1.78)
	Parents	100	89	Ref	Ref
Participation In Clubs	Yes	76	80	Ref	Ref
	No	96	180	1.87 (1.29, 2.71)	1.69 (1.09, 2.62)*
Adherence to HAART	Good	75	181	Ref	Ref
	Poor	97	79	3.15 (2.26, 4.38)	1.29 (0.87, 1.99)
Functional Status	Working	41	247	Ref	Ref
	Not able to work	131	13	2.27 (1.73, 2.99)	1.84 (1.13, 2.22)*
CD4 Count	<200 cell/ mm3	29	62	2.03 (1.38, 2.98)	1.95 (1.18, 3.21)*
	200–350 cell/ml	60	44	5.54 (3.28, 9.36)	0.74 (0.50, 1.08)
	>350 cell/ml	171	66	Ref	Ref
Body Mass Index in Kg/m2	18.5–24.4	102	166	Ref	Ref
	<18.4	57	36	3.64 (2.99, 6.68)	1.06 (0.52, 2.12)
	>24.5	13	58	2.74 (1.43, 5.25)	2.04 (0.95, 4.36)
Isoniazid Preventive Therapy	Yes	48	20	Ref	Ref
	No	124	240	6.01 (4.24, 8.52)	2.57 (1.62, 4.06)*
Opportunistic Infection	Yes	122	108	3.07 (2.20, 4.29)	3.13 (2.17, 4.52)*
	No	50	152	Ref	Ref
Drug Side Effect	Yes	57	46	1.72 (1.25, 2.37)	1.44 (1.02, 2.04)*
	No	115	214	Ref	Ref
Types of Follow-up	Routine	120	146	Ref	Ref
	ASM	52	114	1.49 (1.08, 2.07)	1.09(0.076, 1.58)
Viral Load	<1,000 Copies	66	179	Ref	Ref
	≥1,000 Copies	21	13	1.89 (1.16, 3.06)	3.15 (1.81, 5.47)*
	Not done	85	68	1.3 (1.12, 2.13)	1.22 (0.46, 3.21)

^*p < 0.05 (significance). Ref, reference category; ASM, appointment spacing model; HAART, highly active antiretroviral therapy; LTFU, loss to follow-up.